Literature DB >> 9860408

Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C.

N Bayati1, A L Silverman, S C Gordon.   

Abstract

OBJECTIVE: The clinical and morphological significance of a raised alpha-fetoprotein (AFP) level in patients with chronic hepatitis C is undefined. We sought to determine the relation between serum AFP level and liver histology in this population.
METHODS: We reviewed the clinical and histological records of 200 consecutively evaluated patients with chronic hepatitis C whose serum AFP levels were recorded. Two groups were studied: group I = 125/200 (62%) patients with normal AFP, < 10 ng/ml; and group II = 75/200 (38%) patients with raised AFP, > 10 ng/ml. The groups were compared according to age, gender, duration of disease, histology, and history of alcohol abuse.
RESULTS: There was no significant difference in serum AFP based on age, gender, alcohol consumption, or disease duration. Significant histological differences were observed: cirrhosis was present in 57 (45%) patients in group I versus 51 (68%) in group II (p < 0.001). Hepatocellular carcinoma was more frequent in group II (14/75 [19%]) than in group I (1/125 [1%]) (p < 0.001). Ten of 77 (13%) noncirrhotic patients and 51/108 (47%) cirrhotic patients had a raised AFP (p < 0.002; relative risk, 3.262; confidence interval [C.I.], 1.912-5.564). A derived AFP level of 17.8 ng/ml maximized specificity for predicting histological outcome: one of 76 (1.3%), 29/108 (26.8%), and 14/15 (93.3%) patients were noncirrhotic, cirrhotic, or had HCC, respectively. This derived AFP value is 35% sensitive and 98.6% specific for cirrhosis, with a positive predictive value of 97.7%.
CONCLUSION: A serum AFP level >17.8 ng/ml strongly suggests the diagnosis of cirrhosis in a population of patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860408     DOI: 10.1111/j.1572-0241.1998.00703.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Surveillance for hepatocellular carcinoma: in whom and how?

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

3.  Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.

Authors:  Aldo Spadaro; Antonino Ajello; Carmelo Luigiano; Carmela Morace; Maria Letizia Resta; Grazia Berlinghieri; Salvatore Campo; Claudio Scisca; Angela Alibrandi; Graziella D'Arrigo; Nunziata Alessi; Oscar Ferrau; Maria Antonietta Freni
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Authors:  Barham K Abu Dayyeh; May Yang; Bryan C Fuchs; Daniel L Karl; Suguru Yamada; John J Sninsky; Thomas R O'Brien; Jules L Dienstag; Kenneth K Tanabe; Raymond T Chung
Journal:  Gastroenterology       Date:  2011-03-24       Impact factor: 22.682

5.  Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients.

Authors:  Faisal M Sanai; Samia Sobki; Khalid I Bzeizi; Shaffi A Shaikh; Khalid Alswat; Waleed Al-Hamoudi; Majid Almadi; Faisal Al Saif; Ayman A Abdo
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

6.  Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Toshiya Osawa; Yasuyuki Araki; Kouichi Takaguchi; Youichi Morimoto; Noriaki Hashimoto; Kousaku Sakaguchi; Tatsuro Sakata; Masaharu Ando; Yasuhiro Makino; Shuji Matsumura; Hiroki Takayama; Hiroyuki Seki; Shintarou Nanba; Yuki Moritou; Tetsuya Yasunaka; Hideki Ohnishi; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  World J Hepatol       Date:  2015-09-08

7.  Male-like sexual behavior of female mouse lacking fucose mutarotase.

Authors:  Dongkyu Park; Dongwook Choi; Junghoon Lee; Dae-sik Lim; Chankyu Park
Journal:  BMC Genet       Date:  2010-07-07       Impact factor: 2.797

8.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

9.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

10.  Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Yasushi Tamura; Satoshi Yamagiwa; Yohei Aoki; So Kurita; Takeshi Suda; Shogo Ohkoshi; Minoru Nomoto; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.